Assessment of Venous Thrombus Characteristics in Renal Cell Carcinoma Patients Through Volumetric Computed Tomography First-Order Radiomic Features - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of Venous Thrombus Characteristics in Renal Cell Carcinoma Patients Through Volumetric Computed Tomography First-Order Radiomic Features

  • By

  • Paweł Kowal

  • Krzysztof Ratajczyk

  • Wiktor Bursiewicz

  • Maciej Trzciniecki

  • Karolina Marek-Bukowiec

  • Joanna Rogala

  • Yulian Mytsyk

  • February 4, 2026

Share

Clinical Scorecard: Assessment of Venous Thrombus Characteristics in Renal Cell Carcinoma Patients Through Volumetric Computed Tomography First-Order Radiomic Features

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients diagnosed with renal cell carcinoma exhibiting venous tumor thrombus requiring surgical intervention.
Care Setting

Key Highlights

  • Add specific statistics for 3-year and 5-year OS rates.

Guideline-Based Recommendations

Diagnosis

    Management

    • Perform radical nephrectomy with thrombectomy for localized RCC with VTT, considering tumor size and extent.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Surgical approaches are complex and require careful preoperative imaging assessment, considering potential complications.

        Clinical Best Practices

        • Utilize advanced imaging techniques such as 3D modeling and machine learning for accurate thrombus characterization.

        Related Resources & Content

        Original Source(s)

        Assessment of Venous Thrombus Characteristics in Renal Cell Carcinoma Patients Through Volumetric Computed Tomography First-Order Radiomic Features

        • by Paweł Kowal, Krzysztof Ratajczyk, Wiktor Bursiewicz, Maciej Trzciniecki, Karolina Marek-Bukowiec, Joanna Rogala, Yulian Mytsyk

        • February 4, 2026

        Related Content

        This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark

        REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR

        • May 25, 2026

        • 7 min
        Endogenous Competition of circ_001024 for miR-145-3p: Implications for GLUT5 Regulation in Renal Cell Carcinoma

        Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer

        Genetic testing may be the most effective way for researchers to distinguish between a rare form of kidney cancer and another that is more common, potentially preventing misdiagnoses, according to a recent study by researchers at Fox Chase Cancer Center and Temple University Hospital.

        • October 8, 2025

        • 3 min